Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus Rituximab in Relapsed/Refractory Follicular Lymphoma
NCT01902862Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in follicular lymphoma (FL), sponsored by Janssen Pharmaceutical. Started Feb 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01902862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01902862.